Prostate Cancer

CVD Risk in Prostate Cancer: Future Directions in Care

April 13th 2022, 1:00pm


Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.

Multidisciplinary Care in Prostate Cancer and CVD Management

April 6th 2022, 1:20pm


Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.

CVD Risk in Prostate Cancer: Quality Measures and Coverage Policy

April 6th 2022, 1:00pm


Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.

What Evidence Is Needed to Further Define CVD Risk in Prostate Cancer?

March 30th 2022, 1:20pm


Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.

Factors in Evaluating Therapy for Prostate Cancer

March 30th 2022, 1:00pm


Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.

CVD in Prostate Cancer: Risk-Bearing Practices and Alternative Payment Models

March 23rd 2022, 1:20pm


Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.

Impact of CVD Risk on Cost of Care in Prostate Cancer

March 23rd 2022, 1:00pm


Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.

Prostate Cancer and CVD: Professional Society Guidelines

March 16th 2022, 1:20pm


Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.

Prostate Cancer: Identifying Patients at Risk for CVD

March 16th 2022, 1:00pm


A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.

CVD Risk Associated With ADT in Prostate Cancer

March 9th 2022, 2:20pm


Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.